Showing 1 - 7 results of 7 for search 'Richard L. Wasserman', query time: 0.03s Refine Results
  1. 1
    Long-term adverse events, efficacy, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin in patients aged < 18 years with primary immunodeficiency diseases

    Long-term adverse events, efficacy, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin in patients aged < 18 years with primary... by Lina Laguado, Richard L. Wasserman, Isaac Melamed, Lisa Kobrynski, Sudhir Gupta, Werner Engl, Heinz Leibl, Leman Yel

    Published 2018-06-01
    Get full text
    Article
  2. 2
    Heat-induced alterations in cashew allergen solubility and IgE binding

    Heat-induced alterations in cashew allergen solubility and IgE binding by Christopher P. Mattison, Yvette Bren-Mattison, Barry Vant-Hull, Aurora M. Vargas, Richard L. Wasserman, Casey C. Grimm

    Published 2016-01-01
    Get full text
    Article
  3. 3
    Microbiological, Physicochemical, and Immunological Analysis of a Commercial Cashew Nut-Based Yogurt

    Microbiological, Physicochemical, and Immunological Analysis of a Commercial Cashew Nut-Based Yogurt by Christopher P. Mattison, Kayanush J. Aryana, Kristen Clermont, Eric Prestenburg, Steven W. Lloyd, Casey C. Grimm, Richard L. Wasserman

    Published 2020-11-01
    Get full text
    Article
  4. 4
    Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies

    Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies by Elena E. Perez, Jacques Hébert, Anne K. Ellis, Oral Alpan, William R. Lumry, Ralph Shapiro, Daniel Suez, J. Fernando Mandujano, Richard L. Wasserman

    Published 2021-07-01
    Get full text
    Article
  5. 5
    Local adverse reaction rates decreased over time during treatment with recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin G (fSCIG) in patients with primary immunodeficiency diseases in the fSCIG phase 3 studies

    Local adverse reaction rates decreased over time during treatment with recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin G (fSCIG) in patients wit... by Lina Laguado, Mark Stein, Richard L. Wasserman, Isaac Melamed, Sudhir Gupta, Lisa Kobrynski, Arye Rubinstein, Christopher J. Rabbat, Werner Engl, Barbara McCoy, Heinz Leibl, Leman Yel

    Published 2018-06-01
    Get full text
    Article
  6. 6
    Towards an FDA-cleared basophil activation test

    Towards an FDA-cleared basophil activation test by Oral Alpan, Richard L. Wasserman, Theodore Kim, Amy Darter, Atul Shah, Douglas Jones, Donald McNeil, Henry Li, Laura Ispas, Melinda Rathkopf, Elena Perez, Dareen Siri, Maeve O’Connor, Matthew Plassmeyer, Kimberly Romito, Christina Pettibone, Sean O’Reilly, Søren Ulrik Sønder, Gerald Marti

    Published 2023-01-01
    Get full text
    Article
  7. 7
    Recurrent Granulibacter bethesdensis Infections and Chronic Granulomatous Disease

    Recurrent Granulibacter bethesdensis Infections and Chronic Granulomatous Disease by David E. Greenberg, Adam R. Shoffner, Adrian M. Zelazny, Michael E. Fenster, Kol A. Zarember, Frida Stock, Li Ding, Kimberly R. Marshall-Batty, Richard L. Wasserman, David F. Welch, Kishore Kanakabandi, Dan E. Sturdevant, Kimmo Virtaneva, Stephen F. Porcella, Patrick R. Murray, Harry L. Malech, Steven M. Holland

    Published 2010-09-01
    Get full text
    Article

Search Tools: